Nautilus Biotechnology Inc
NASDAQ:NAUT
Nautilus Biotechnology Inc
NASDAQ:NAUT
Price:
3.91
USD
-1.01%
Market Closed
Market Cap:
$494.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Nautilus Biotechnology Inc
NASDAQ:NAUT
|
US |
|
Indosat Tbk PT
IDX:ISAT
|
ID |
|
Gear Energy Ltd
TSX:GXE
|
CA |
|
Galliford Try Holdings PLC
LSE:GFRD
|
UK |
|
Wakita & Co Ltd
TSE:8125
|
JP |
|
H
|
Hanjin Heavy Ind & Const Holdings Co Ltd
KRX:003480
|
KR |
|
Network People Services Technologies Ltd
NSE:NPST
|
IN |
Balance Sheet
Balance Sheet Decomposition
Nautilus Biotechnology Inc
Nautilus Biotechnology Inc
Balance Sheet Decomposition is not available for
Nautilus Biotechnology Inc
Nautilus Biotechnology Inc
Balance Sheet
Nautilus Biotechnology Inc
Nautilus Biotechnology Inc
Currency: USD
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
1
|
37
|
186
|
115
|
19
|
28
|
12
|
|
| Cash Equivalents |
1
|
37
|
186
|
115
|
19
|
28
|
12
|
|
| Short-Term Investments |
16
|
40
|
160
|
70
|
154
|
102
|
91
|
|
| Other Current Assets |
0
|
1
|
4
|
3
|
3
|
3
|
3
|
|
| Total Current Assets |
17
|
78
|
349
|
187
|
177
|
133
|
106
|
|
| PP&E Net |
1
|
6
|
32
|
33
|
37
|
32
|
31
|
|
| PP&E Gross |
1
|
6
|
32
|
33
|
37
|
32
|
31
|
|
| Accumulated Depreciation |
1
|
1
|
2
|
3
|
5
|
7
|
8
|
|
| Long-Term Investments |
0
|
0
|
16
|
129
|
91
|
76
|
53
|
|
| Other Long-Term Assets |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Assets |
19
N/A
|
85
+359%
|
399
+369%
|
350
-12%
|
306
-13%
|
243
-21%
|
191
-21%
|
|
| Liabilities | ||||||||
| Accounts Payable |
0
|
1
|
2
|
1
|
2
|
1
|
1
|
|
| Accrued Liabilities |
0
|
3
|
4
|
6
|
7
|
7
|
7
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
3
|
6
|
7
|
9
|
8
|
8
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
3
|
29
|
28
|
31
|
26
|
26
|
|
| Total Liabilities |
1
N/A
|
6
+1 160%
|
35
+454%
|
35
+1%
|
40
+15%
|
34
-15%
|
34
+0%
|
|
| Equity | ||||||||
| Common Stock |
33
|
108
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
15
|
30
|
81
|
139
|
202
|
273
|
332
|
|
| Additional Paid In Capital |
0
|
1
|
444
|
455
|
468
|
482
|
489
|
|
| Other Equity |
0
|
0
|
0
|
2
|
0
|
0
|
0
|
|
| Total Equity |
18
N/A
|
79
+335%
|
364
+362%
|
315
-13%
|
265
-16%
|
209
-21%
|
157
-25%
|
|
| Total Liabilities & Equity |
19
N/A
|
85
+359%
|
399
+369%
|
350
-12%
|
306
-13%
|
243
-21%
|
191
-21%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
124
|
124
|
124
|
125
|
125
|
126
|
126
|
|
Switch to:
Switch to:
See Also
Discover More
